CASE PH-7054 DIV2

OF E JAMES TRACES

CERTIFICATE OF MAILING

thereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Eileen Immordino

Type or print name

Signatura

June 23, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

KO ET AL.

APPLICATION NO: 10/809,772

FILED: MARCH 25, 2004

FOR: HETEROCYCLIC PIPERIDINES AS MODULATORS OF

CHEMOKINE RECEPTOR ACTIVITY

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/465,949 filed December 17, 1999, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicants

Reg. No. 39,408

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4379

Date: June 22, 2004

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

STEAT & THE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1

Complete if Known					
Application Number	10/809,772				
Filing Date	March 25, 2004				
First Named Inventor	Ko et al.				
Group Art Unit					
Examiner Name					
Attorney Docket Number	PH-7054 DIV2				

U.S. PATENT DOCUMENTS							
		U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Cite No.1	Number Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
		2684965	Weston et al.	07/27/1954			
		3133061	Kirchner et al.	05/12/1964			
		4943578	Naylor et al.	07/24/1990			
		5116842	Naylor et al.	05/26/1992			
		5512567	Terada et al.	04/30/1996			
		5646151	Kruse et al.	07/08/1997			
		5688955	Kruse et al.	11/18/1997			
		5744458	Kruse et al.	04/28/1998			

	• • •			FOREIG	N PATENT DOCU	IMENTS		
Examiner Initials*	Cite No.1	For Office ³	eign Patent Doo Number ⁴	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
			93/20099		WIPO	10/14/1993		
			95/19344		WIPO	07/20/1995	·	
			97/17954		WIPO	05/22/1997		
		i	97/22597		WIPO	06/26/1997		
			97/24324		WIPO	07/10/1997		
	<u> </u>	1	97/48681		WIPO	12/24/1997		
			98/25604	<u> </u>	WIPO	06/18/1998		
			98/25617		WIPO	06/18/1998		
			98/27815		WIPO	07/02/1998		
			98/31364		WIPO	07/23/1998		
			99/09984		WIPO	03/04/1999		
			99/04794		WIPO	02/04/1999		
			0747357		EUROPE	06/05/1996		
			2013179	T T	GERMAN	10/01/1970		
		1	3163067		JAPAN	07/01/1991	*	
	<u> </u>	1	3163068		JAPAN	07/01/1991		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		KHANDELWAL et al, Agents Acting on CNS, Indian J. Chem. 16B, pp. 1012-1014.				
		BIRCH et al., Preparation and Evaluation of Some Hydrophilic Phenylacetl-Piperazines as Peripherally Selective k-Opioid Receptor Agonists, Bioorganic & Medicinal Chemistry Letters, 1992, pp. 1275-1278, Volume 2, No. 10.				
		NAYLOR et al., A Potent New Class of k-Receptor Agonist: 4-Substututed 1-(Arylacetyle)-2-[(Dialkylamino)Methyl]Piperazines, J. Med. Chem., 1993, pp. 2075-2083, Volume 36.				
		HESSELGESSER et al., Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor, The Journal of Biological Chemistry, 1998, pp. 15687-15692, Volume 273, No. 25.				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.Burden Hr Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Pacework Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

MENT'S TRAC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known					
Application Number	10/809,772				
Filing Date	March 25, 2004				
First Named Inventor	Ko et al.				
Group Art Unit					
Examiner Name					
Attorney Docket Number	PH-7054 DIV2				

U.S. PATENT DOCUMENTS							
		U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Cite Initials No.	Number Kind Code ² (if known)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
	1	2684965	Weston et al.	07/27/1954			
		3133061	Kirchner et al.	05/12/1964			
		4943578	Naylor et al.	07/24/1990			
		5116842	Naylor et al.	05/26/1992			
	<u> </u>	5512567	Terada et al.	04/30/1996			
		5646151	Kruse et al.	07/08/1997			
		5688955	Kruse et al.	11/18/1997			
		5744458	Kruse et al.	04/28/1998			

FOREIGN PATENT DOCUMENTS									
Examiner Initials* •	Cite No.1	For Office ³	eign Patent Doc Number ⁴		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ₆	
			93/20099		WIPO	10/14/1993			
		† ·	95/19344		WIPO	07/20/1995			
		· ·	97/17954		WIPO	05/22/1997			
		1	97/22597		WIPO	06/26/1997			
		<u> </u>	97/24324		WIPO	07/10/1997			
			97/48681		WIPO	12/24/1997			
	· · ·	1	98/25604	1	WIPO	06/18/1998			
			98/25617		WIPO	06/18/1998			
		—	98/27815		WIPO	07/02/1998			
-			98/31364		WIPO	07/23/1998			
		<u> </u>	99/09984		WIPO	03/04/1999			
			99/04794	1	WIPO	02/04/1999			
			0747357		EUROPE	06/05/1996			
,		T	2013179		GERMAN	10/01/1970			
	l	<u> </u>	3163067		JAPAN	07/01/1991			
	<u> </u>	<u> </u>	3163068		JAPAN	07/01/1991			

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		KHANDELWAL et al, Agents Acting on CNS, Indian J. Chem. 16B, pp. 1012-1014.				
		BIRCH et al., Preparation and Evaluation of Some Hydrophilic Phenylacetl-Piperazines as Peripherally Selective k-Opioid Receptor Agonists, Bioorganic & Medicinal Chemistry Letters, 1992, pp. 1275-1278, Volume 2, No. 10.				
		NAYLOR et al., A Potent New Class of k-Receptor Agonist: 4-Substututed 1-(Arylacetyle)-2-[(Dialkylamino)Methyl]Piperazines, J. Med. Chem., 1993, pp. 2075-2083, Volume 36.				
		HESSELGESSER et al., Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor, The Journal of Biological Chemistry, 1998, pp. 15687-15692, Volume 273, No. 25.				

	·		
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant. Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached. Burden Hr Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.